| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
Exhibit E – Form of Akron BioManufacturing Release Agreement |
| 14 Oct 2026 |
8-K: Results of Operations and Financial Condition
MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue |
| 17 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the 2026 annual meeting of stockholders of MaxCyte, Inc. (the “Company”) held on June 17, 2026 (the “Annual Meeting”), the Company’s stockholders considered and approved two proposals, each of which is described in more detail in the ... |
| 16 Jun 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2026, on March 16, 2026, MaxCyte, Inc. (the “Company”) received notice from the Listing Qualifications staff of The Na... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue |
| 27 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) – MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gener... |
| 24 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement |
| 20 Mar 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On March 16, 2026, MaxCyte, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock had fallen... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
ROCKVILLE, MD, January 12, 2026 — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generati... |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ROCKVILLE, MD, November 12, 2025 — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell th... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
MaxCyte will now host its earnings conference call on November 12, 2025 |
| 22 Sep 2025 |
8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure
ROCKVILLE, MD, September 22, 2025 — MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell t... |
| 11 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 11, 2025, Ali Soleymannezhad’s employment as Chief Commercial Officer of MaxCyte, Inc. (the “Company”), ended. Mr. Soleymannezhad, in accordance with the terms of his Amended and Restated Severance Agreement dated July 1, 2024,... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ROCKVILLE, MD, August 6, 2025 — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell thera... |
| 25 Jun 2025 |
8-K: Other Events
On June 25, 2025, MaxCyte, Inc. (the “Company”) announced that it had applied to the London Stock Exchange plc (the “LSE”) to cancel its admission of the Company’s common stock (the “Shares”) to trading on the AIM market (“AIM”) of the L... |
| 18 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Defined Terms. Except as otherwise provided, any capitalized term shall have the meaning provided in Section 14 of this Plan. |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation ce... |
| 11 Mar 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ROCKVILLE, MD, March 11, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation... |
| 30 Jan 2025 |
8-K: Regulation FD Disclosure
ROCKVILLE, MD – January 30, 2025 – MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics... |
Loading...